Executive Summary
Across 56 SEC 8-K filings from the USA S&P 500 Industrials stream (primarily reflecting aerospace, machinery, transportation, construction, but with heavy banking/pharma crossovers), the dominant theme is a surge in M&A activity with 18 filings (32%) disclosing Item 2.01 completions or Item 1.01 new agreements (e.g., Fifth Third Bancorp, Huntington Bancshares, PotlatchDeltic), signaling sector consolidation amid neutral sentiment (54/56 neutral/mixed). Governance disruptions are prevalent in 22 filings (39%) via Item 5.02 officer/director changes and Item 5.03 amendments (e.g., TTM Technologies, Stoneridge), potentially indicating integration or strategic shifts. Reg FD disclosures appear in 18 filings (32%) under Item 7.01 (e.g., Global Net Lease, IDEXX Laboratories), often paired with exhibits suggesting preliminary earnings or updates, while 9 filings (16%) report Item 2.02 results without quantitative trends disclosed. No period-over-period metrics, insider trades, capital allocation details, or forward-looking guidance are quantified across any filing, limiting numerical trend synthesis but highlighting disclosure opacity as a portfolio risk; high materiality scores (7-9/10 in 22 filings) flag time-sensitive opportunities in M&A synergies vs. risks from undisclosed terms, control changes, and delistings. Overall, neutral sentiment masks actionable consolidation plays in industrials-adjacent firms, with banking-heavy filings implying cross-sector spillovers.
Tracking the trend? Catch up on the prior S&P 500 Industrials Sector SEC Filings digest from January 29, 2026.
Investment Signals(12)
- Fifth Third Bancorpβ(BULLISH)β²
Completed acquisition (Item 2.01) with potential pro-growth strategic benefits and governance efficiency gains (Item 5.03), materiality 7/10
- Huntington Bancsharesβ(BULLISH)β²
Acquisition completion (Item 2.01) may deliver unquantified scale/synergies, pro forma exhibits available (Item 9.01), materiality 8/10
- PotlatchDeltic Corpβ(BULLISH)β²
Asset acquisition completion (Item 2.01) amid control shift, financial exhibits for assessment (Item 9.01), high materiality 9/10
- Stoneridge Incβ(BULLISH)β²
Acquisition completion (Item 2.01) + Reg FD disclosure (Item 7.01) signals potential positive updates/synergies, materiality 7/10
- Advanced Drainage Systemsβ(BULLISH)β²
Acquisition completion (Item 2.01) in construction/industrials space + Reg FD (Item 7.01), strategic expansion potential
- Heritage Financial Corpβ(BULLISH)β²
Acquisition completion (Item 2.01) with Reg FD exhibits, scale opportunity in industrials-adjacent banking, materiality 8/10
- Third Coast Bancsharesβ(BULLISH)β²
Acquisition completion (Item 2.01) + officer elections (Item 5.02) for integration, Reg FD updates (Item 7.01), materiality 8/10
- Venture Globalβ(BULLISH)β²
New material definitive agreement (Item 1.01) flags strategic expansion/partnership upside
- ImmuCell Corpβ(BULLISH)β²
Material agreement (Item 1.01) + new officer appointments (Item 5.02) align incentives for growth, materiality 8/10
- IDEXX Laboratoriesβ(BULLISH)β²
Item 2.02 results + exhibits (Item 9.01) in vet diagnostics (industrials adjacent), no negative indicators, materiality 7/10
- Devon Energyβ(BULLISH)β²
Material agreement (Item 1.01) + Reg FD (Item 7.01), potential industrials energy tie-in
- Global Net Leaseβ(BULLISH)β²
Reg FD voluntary disclosure (Item 7.01) with exhibits, low risk clean signal
Risk Flags(10)
- PotlatchDeltic Corp/Control Changeβ[HIGH RISK]βΌ
Changes in control (Item 5.01) + delisting notice (Item 3.01) + security holder rights mods (Item 3.03), reduces liquidity, high risk/materiality 9/10
- Fifth Third Bancorp/Financial Obligationβ[MEDIUM RISK]βΌ
New off-balance sheet arrangement (Item 2.03) + rights mods (Item 3.03), unknown impacts medium risk
- Huntington Bancshares/Governanceβ[MEDIUM RISK]βΌ
Security holder rights changes (Item 3.03) + governance shifts (5.02/5.03), potential dilution/control risks, materiality 8/10
- Regen BioPharma/Dilutionβ[HIGH RISK]βΌ
Unregistered equity sales (Item 3.02), bearish sentiment signals shareholder dilution, medium risk
- Claros Mortgage Trust/Multiple Risksβ[HIGH RISK]βΌ
Agreement termination (Item 1.02) + new obligation (Item 2.03) + equity sales (Item 3.02) + governance change (Item 5.03), mixed sentiment/materiality 8/10
- Newbridge Acquisition/M&A Uncertaintyβ[MEDIUM RISK]βΌ
Material agreement likely merger (Item 1.01) + equity sales (Item 3.02), undisclosed terms/approval risks, materiality 8/10
- Lottery.com/Agreement Shiftβ[MEDIUM RISK]βΌ
New agreement (Item 1.01) offsets termination (Item 1.02), mixed sentiment lacks net impact clarity, materiality 8/10
- SunPower Inc/Transaction Opacityβ[MEDIUM RISK]βΌ
Acquisition completion (Item 2.01) + equity sales (Item 3.02), undisclosed details amplify uncertainty
- Lexicon Pharmaceuticals/Governanceβ[MEDIUM RISK]βΌ
Multi-risks incl. equity sales (3.02), rights mods (3.03), amendments (5.03), materiality 8/10
- TTM Technologies/Officer Changeβ[LOW-MEDIUM RISK]βΌ
Undisclosed officer departure/appointment (Item 5.02), potential leadership instability
Opportunities(10)
- Fifth Third Bancorp/M&Aβ(OPPORTUNITY)β
Strategic benefits from completed acquisition if pro-growth, monitor exhibits for synergies
- Huntington Bancshares/Synergiesβ(OPPORTUNITY)β
Acquisition scale + pro forma statements in exhibits, assess for undervalued integration alpha
- Stoneridge Inc/Acquisition + FDβ(OPPORTUNITY)β
Synergies from Item 2.01 deal + positive Reg FD potential in industrials electronics
- Venture Global/Partnershipβ(OPPORTUNITY)β
Material agreement for expansion/financing, low disclosed negatives
- ImmuCell Corp/Growth Initiativeβ(OPPORTUNITY)β
Material agreement + officer incentives align for upside, high materiality
- Advanced Drainage Systems/Construction M&Aβ(OPPORTUNITY)β
Deal completion positions for infrastructure tailwinds
- Heritage Financial/Scaleβ(OPPORTUNITY)β
Acquisition + Reg FD for industrials banking crossover growth
- Third Coast Bancshares/Integrationβ(OPPORTUNITY)β
Post-acquisition officer changes + FD disclosure for efficiency gains
- IDEXX Laboratories/Earningsβ(OPPORTUNITY)β
Item 2.02 results in Phase 1 enriched context, potential beat via exhibits
- PotlatchDeltic/Transformationβ(OPPORTUNITY)β
Despite risks, control shift + acquisition could unlock forest products value
Sector Themes(6)
- M&A Consolidation Waveβ
18/56 filings (32%) disclose Item 1.01/2.01 (e.g., 8 completions), implying industrials/banking sector pursuing scale amid neutral sentiment; watch for synergies vs. integration costs
- Governance Overhaul Patternβ
22/56 (39%) with Item 5.02/5.03 changes (e.g., officer turnover in Stoneridge, TTM), avg materiality 5/10, signals leadership refreshes or M&A fallout; potential efficiency gains
- Reg FD Disclosure Clusterβ
18/56 (32%) Item 7.01 filings (e.g., Global Net Lease, Sierra Bancorp) with exhibits, often paired with earnings (Item 2.02 in 9 cases); suggests pre-earnings intel flow, low risk
- Disclosure Opacity Across Boardβ
100% lack quantitative PoP comparisons, insider trades, guidance; high materiality (avg 5.8/10) in 22 cases creates alpha from digging exhibits, but elevates uncertainty
- Dilution/Equity Risks Emergingβ
6 filings with Item 3.02 unregistered sales (e.g., Claros, Regen bearish), tied to M&A; monitor for shareholder value erosion in smaller caps
- Neutral-to-Mixed Sentiment Dominanceβ
54/56 neutral/mixed (2 mixed: Lottery.com, Claros; 1 bearish: Regen), no bullish quant flags; portfolio implication: wait for exhibits/clarifications before positioning
Watch List(8)
Monitor liquidity impact post-delisting (Item 3.01) + control change effects, exhibits for financials; imminent Feb 2026
Track rights modifications (Item 3.03) + acquisition integration risks via follow-up filings
Watch terminations/new obligations (1.01/1.02) + equity sales for dilution, Reg FD updates
Bearish unregistered sales (3.02), monitor dilution extent and use of proceeds
Multiple filings (10,53) on officer changes + acquisition; watch leadership stability post-Feb 2026
Dual filings (13,20) Item 2.02/7.01, track earnings call for PoP trends not disclosed
Complex risks (1.01,3.02,5.03), monitor for guidance in upcoming exhibits
Post-deal officer changes + Reg FD, watch Q1 2026 earnings for synergies realization
Filing Analyses(56)
02-02-2026
Fifth Third Bancorp filed an 8-K on 2026-02-02 reporting completion of an acquisition or disposition of assets (Item 2.01), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), material modifications to rights of security holders (Item 3.03), departure of directors/officers, election of directors, appointment of officers, and compensatory arrangements (Item 5.02), amendments to articles of incorporation or bylaws and change in fiscal year (Item 5.03), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No quantitative financial metrics, deal values, parties involved, synergies, or impacts were disclosed, resulting in no identifiable positive or negative performance indicators.
02-02-2026
Lottery.com Inc. filed an 8-K on 2026-02-02 reporting entry into a new Material Definitive Agreement under Item 1.01 and termination of a prior Material Definitive Agreement under Item 1.02. No details on the nature, parties, dollar values, strategic rationale, or financial impacts of either agreement are disclosed. This multi-item filing indicates a strategic shift with a new commitment offsetting the end of a previous one, but lacks quantification to assess net effects.
02-02-2026
Global Net Lease, Inc. filed an 8-K on February 02, 2026 (AccNo: 0001104659-26-008874, Size: 381 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of potentially material information via Reg FD and attached exhibits. No specific transaction details, financial metrics, or quantitative data are disclosed in the provided filing information.
02-02-2026
PotlatchDeltic Corp filed an 8-K on 2026-02-02 announcing the completion of an acquisition or disposition of assets under Item 2.01, notice of delisting or failure to satisfy a continued listing rule or standard under Item 3.01, material modifications to rights of security holders under Item 3.03, changes in control of the registrant under Item 5.01, departures or elections of directors/officers and compensatory arrangements under Item 5.02, and amendments to articles of incorporation or bylaws or change in fiscal year under Item 5.03. Item 9.01 includes financial statements and exhibits. No quantitative financial details, transaction values, parties involved, or performance metrics are disclosed.
02-02-2026
IDEXX Laboratories Inc filed an 8-K on February 2, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics, guidance, or other quantitative details are available.
02-02-2026
Venture Global, Inc. filed a Form 8-K on 2026-02-02 under Item 1.01 disclosing entry into a material definitive agreement. No specific details on the agreement's parties, transaction value, financial terms, strategic rationale, or impacts were provided. This mandatory disclosure signals a potentially significant event, but lacks quantitative data for impact assessment.
02-02-2026
TTM Technologies Inc filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, appointment or resignation, reasons, or timing are provided in the available information. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.
02-02-2026
Eton Pharmaceuticals, Inc. filed a Form 8-K on February 2, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, financial statements, or exhibits are disclosed in the provided filing summary. This is a multi-item informational filing with no quantified metrics, impacts, or directional biases reported.
02-02-2026
Stoneridge Inc. filed an 8-K on February 02, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.01 completion of an acquisition or disposition of assets. The filing also covers Item 5.02 changes in directors or certain officers, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. No quantitative metrics, deal values, parties involved, or financial terms are disclosed.
02-02-2026
Quantum Corp /DE/ filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), with additional Other Events under Item 8.01 and exhibits under Item 9.01. No specific details such as the key position affected, names of individuals, appointment or resignation status, reasons for the change, or any quantitative data are disclosed in the provided filing summary. No positive or negative metrics, financial impacts, or performance comparisons are mentioned.
02-02-2026
Sierra Bancorp filed an 8-K on 2026-02-02 under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, or other quantitative financial details are provided in the filing summary. This appears to be a standard earnings-related disclosure with no mentioned positive or negative performance indicators.
02-02-2026
Devon Energy Corp filed a multi-item 8-K on February 2, 2026, disclosing entry into a Material Definitive Agreement under Item 1.01, departure/election/appointment of directors/officers and compensatory arrangements under Item 5.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No quantitative details, transaction values, personnel names, financial impacts, or performance metrics (positive, negative, or flat) are provided in the filing summary. This requires review of exhibits for full context.
02-02-2026
Claros Mortgage Trust, Inc. filed a multi-item Form 8-K on February 2, 2026, reporting entry into a material definitive agreement (Item 1.01) alongside termination of another material definitive agreement (Item 1.02). The filing also discloses creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws or change in fiscal year (Item 5.03), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). No quantitative details, dollar values, or specific impacts were disclosed.
02-02-2026
Newbridge Acquisition Ltd filed an 8-K on 2026-02-02 disclosing entry into a Material Definitive Agreement under Item 1.01, likely related to a merger or acquisition, along with unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws and/or change in fiscal year (Item 5.03), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No quantitative metrics, deal terms, parties beyond the filer, valuations, synergies, or performance comparisons (positive, negative, or flat) are disclosed. Critical details such as target company, deal structure, consideration, and timeline remain NOT_DISCLOSED.
02-02-2026
Northfield Bancorp, Inc. filed a Form 8-K on 2026-02-02 disclosing entry into a material definitive agreement under Item 1.01, departure/election/appointment of directors/officers and compensatory arrangements under Item 5.02, Regulation FD disclosure under Item 7.01, and financial statements/exhibits under Item 9.01. No specific details on the agreement, personnel changes, financial impacts, transaction values, or quantitative metrics are provided in the filing summary. This is a multi-item informational filing with no disclosed positive or negative financial metrics.
02-02-2026
NIQ Global Intelligence plc filed an 8-K on 2026-02-02 disclosing results of operations and financial condition under Item 2.02, departure or appointment of directors or certain officers including compensatory arrangements under Item 5.02, and financial statements and exhibits under Item 9.01. No specific details on officer positions, reasons for change, financial metrics, or performance comparisons are disclosed. No quantitative data or directional impacts are provided.
02-02-2026
Sierra Bancorp filed an 8-K on February 2, 2026, reporting under Item 7.01 Regulation FD Disclosure. No specific financial metrics, transactions, events, positive or negative developments, or quantitative data are disclosed in the provided filing information. This appears to be a single-item voluntary disclosure.
02-02-2026
Plumas Bancorp filed a Form 8-K on February 02, 2026 (AccNo: 0001437749-26-002609, Size: 182 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or contents of the exhibits are disclosed in the filing summary. This multi-item filing appears informational with no quantified positive or negative metrics provided.
02-02-2026
Barnwell Industries Inc filed a Form 8-K on 2026-02-02 reporting under Item 1.01 entry into a material definitive agreement, under Item 3.03 material modifications to rights of security holders, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details provided on the agreement, modifications, events, transaction values, financial impacts, or quantitative metrics. No positive or negative performance metrics are disclosed.
02-02-2026
F&M BANK CORP filed an 8-K on February 2, 2026, under Item 2.02 reporting Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed performance data available.
02-02-2026
Advanced Drainage Systems, Inc. filed an 8-K on 2026-02-02 disclosing the completion of an acquisition or disposition of assets under Item 2.01. The filing includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific transaction details, parties, values, or financial metrics were disclosed in the provided filing summary.
02-02-2026
Flutter Entertainment plc filed a Form 8-K on 2026-02-02 under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits, with Accession Number 0001193125-26-033050 and file size 137 KB. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the filing summary. This is a voluntary informational disclosure without apparent positive or negative performance indicators.
02-02-2026
CAPITAL CITY BANK GROUP INC filed an 8-K on February 02, 2026, reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing involves a voluntary disclosure of material non-public information with attached exhibits, but specific details of the disclosure, financial metrics, transactions, or events are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, or directional impacts are provided in the filing summary.
02-02-2026
HERITAGE FINANCIAL CORP /WA/ filed an 8-K on 2026-02-02 under Item 2.01 announcing the completion of an acquisition or disposition of assets. The filing also includes Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No quantitative deal terms, parties involved, strategic rationale, or financial metrics are disclosed.
02-02-2026
OptimumBank Holdings, Inc. filed a Form 8-K on 2026-02-02 reporting results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics were disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.
02-02-2026
PROVECTUS BIOPHARMACEUTICALS, INC. filed a Form 8-K on 2026-02-02 disclosing under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year, accompanied by Item 9.01 Financial Statements and Exhibits. No specific details on the nature, effective date, or impact of the amendments or changes are provided. No quantitative financial metrics, positive or negative changes, or other performance data are mentioned.
02-02-2026
Regen BioPharma Inc filed an 8-K on February 2, 2026, specifically under Item 3.02 disclosing unregistered sales of equity securities. No quantitative details such as transaction value, share count, proceeds, or buyer information are disclosed. This is a single-item mandatory filing with no additional positive or negative metrics provided.
02-02-2026
Capitol Federal Financial, Inc. filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). No specific details on the key position affected, individual involved, nature of change (appointment or resignation), reasons, or timing are provided. No quantitative data, financial metrics, or further governance implications are mentioned.
02-02-2026
Hormel Foods Corp /DE/ filed an 8-K on February 2, 2026, disclosing officer changes or appointments under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), submission of matters to a vote of security holders under Item 5.07, and financial statements and exhibits under Item 9.01. No specific details on affected officers, reasons for changes, vote outcomes, or any financial metrics are provided. This appears to be a routine governance and meeting results disclosure with no indicated positive or negative performance metrics.
02-02-2026
MIRA PHARMACEUTICALS, INC. filed a Form 8-K on February 02, 2026, under Item 8.01 Other Events. No specific details of the event, financial metrics, quantitative data, or period-over-period comparisons are disclosed in the provided filing information. This is a single-item voluntary disclosure with no mentioned positive or negative impacts.
02-02-2026
Peoples Bancorp Inc filed an 8-K on 2026-02-02 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary filing to disclose material non-public information in compliance with Regulation FD and attach relevant exhibits. No financial metrics, transactions, or other quantitative details are explicitly stated in the filing summary provided.
02-02-2026
GENELUX Corp filed an 8-K on February 02, 2026 (AccNo: 0001493152-26-004755, size: 40 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses material nonpublic information pursuant to Regulation FD with attached exhibits, but no specific transaction details, financial metrics, or events are stated in the provided summary. No quantitative data, period-over-period comparisons, or directional metrics (positive, negative, or flat) are mentioned.
02-02-2026
FEDERAL AGRICULTURAL MORTGAGE CORP filed an 8-K on February 02, 2026, reporting amendments to its Articles of Incorporation or Bylaws or a change in fiscal year under Item 5.03, with financial statements and exhibits provided under Item 9.01. No specific details on the nature or impact of the amendments, quantitative metrics, transaction values, or financial implications are disclosed in the filing summary. This appears to be an informational governance update with no directional financial data provided.
02-02-2026
FIRST FINANCIAL BANCORP /OH/ filed an 8-K on 2026-02-02 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), with a filing size of 9 MB. No specific financial metrics, transactions, positive or negative changes, or operational details are disclosed in the provided filing summary. This appears to be a voluntary disclosure to comply with Regulation FD, potentially including attached exhibits such as presentations.
- Β·AccNo: 0000708955-26-000011
- Β·Filing size: 9 MB
- Β·Event Type: General Filing
- Β·Multi-item 8-K: Items 7.01 and 9.01
02-02-2026
Bally's Corp filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), other events under Item 8.01, and financial statements/exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, timing, or any named executives are NOT_DISCLOSED. No quantitative metrics, financial data, or scheduled events are mentioned.
02-02-2026
S&T Bancorp Inc filed an 8-K on February 2, 2026, reporting under Item 5.03 amendments to Articles of Incorporation or Bylaws or change in fiscal year, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details, transaction values, financial metrics, or period-over-period comparisons are disclosed in the provided filing information.
02-02-2026
Quaint Oak Bancorp, Inc. filed a Form 8-K on February 2, 2026 (AccNo: 0000927089-26-000017), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item filing for financial results announcement. No specific revenue, earnings, balance sheet changes, guidance, or quantitative metrics are detailed in the provided filing information.
02-02-2026
Bark, Inc. filed a Form 8-K on February 2, 2026 (AccNo: 0001628280-26-004626), disclosing an unspecified event under Item 8.01 (Other Events). No financial metrics, transaction details, quantitative data, positive or negative changes, or operational impacts were mentioned. Sector information was not specified.
02-02-2026
APARTMENT INVESTMENT & MANAGEMENT CO filed a Form 8-K on February 02, 2026, disclosing an unspecified Other Event under Item 8.01. No quantitative data, financial impacts, transaction details, or other metrics are mentioned in the filing information provided. This is a voluntary single-item disclosure with no further specifics on the event.
02-02-2026
Avidia Bancorp, Inc. filed an 8-K on February 2, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, guidance, or other quantitative details are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data available.
02-02-2026
Farmers & Merchants Bancorp filed a Form 8-K on February 2, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely providing material non-public information previously disclosed selectively, with supporting exhibits attached. No specific financial metrics, transactions, or performance details are disclosed in the filing summary.
02-02-2026
Farmers & Merchants Bancorp filed an 8-K on February 2, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons were disclosed in the filing details. This appears to be a standard earnings-related disclosure without quantified metrics.
02-02-2026
Lexicon Pharmaceuticals, Inc. filed a Form 8-K on February 2, 2026, reporting multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). No specific transaction values, financial metrics, share counts, or directional impacts were disclosed. The filing appears informational without quantified positive or negative metrics.
02-02-2026
NRX Pharmaceuticals, Inc. filed an 8-K on 2026-02-02 under Item 5.02 disclosing a matter related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details including key positions affected, names of individuals, reasons for changes, timing, or any quantitative metrics are provided. No positive or negative performance metrics are mentioned.
02-02-2026
SunPower Inc. filed an 8-K on 2026-02-02 disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01). The filing also reports unregistered sales of equity securities (Item 3.02) and attaches financial statements and exhibits (Item 9.01). No specific transaction details, parties, values, or metrics are disclosed.
02-02-2026
STONERIDGE INC filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and any quantitative data are NOT_DISCLOSED. No financial metrics, performance comparisons, or scheduled events are mentioned.
02-02-2026
ImmuCell Corp filed an 8-K on February 2, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 discloses financial statements and exhibits. No specific transaction details, personnel names, financial impacts, dollar values, or quantitative metrics are disclosed.
02-02-2026
DALRADA FINANCIAL CORP filed an 8-K on February 2, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, parties, terms, financial impacts, or quantitative metrics are disclosed in the provided filing summary.
02-02-2026
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, or financial metrics are disclosed.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 56 filings
πΊπΈ More from United States
View all βMarch 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings β March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC